Why the study?
Does COX-2 inhibition with NS-398 prevent the cardioprotective effects of sevoflurane- or olprinone-induced preconditioning and postconditioning in a rat model of myocardial infarction?
Does COX-2 inhibition with NS-398 prevent the cardioprotective effects of sevoflurane- or olprinone-induced preconditioning and postconditioning in a rat model of myocardial infarction?
Cyclooxygenase 2 appears to be a critical mediator of sevoflurane-induced, but not olprinone-induced, early-phase preconditioning and postconditioning against myocardial infarction in rat hearts.
COX-2 inhibition blocks sevoflurane cardioprotection in rats but spares olprinone; leaves open translation to human preconditioning.
PURPOSE: It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mechanisms of sevoflurane- and olprinone-induced early-phase preconditioning (E-PreC) and postconditioning (PostC) in rat hearts. METHODS: Male Sprague-Dawley rats were anesthetized with sodium pentobarbital. After opening the chest, all rats underwent 30-minute occlusion of left anterior descending coronary artery followed by 2-hour reperfusion, and the infarct size was measured after the reperfusion. The rats were randomly assigned to groups with pre- and postischemic exposure to sevoflurane and administration of olprinone with or without a selective COX-2 inhibitor, NS-398. RESULTS: The infarct size in the control group was 42% ± 6% of the area at risk. Infarct size was significantly reduced by pre- and postischemic administration of sevoflurane (16% ± 7% and 17% ± 6%, respectively), as well as by olprinone (14% ± 4% and 15% ± 10%, respectively). NS-398 prevented the protective effects of both pre- and postischemic exposure to sevoflurane (35% ± 8% and 42% ± 10%, respectively), whereas the protective effect of both pre- and postischemic administration of olprinone was not influenced by NS-398 (12% ± 5% and 19% ± 7%, respectively). CONCLUSIONS: Cyclooxygenase 2 could be a critical mediator of sevoflurane-induced but not olprinone-induced E-PreC or PostC in rat hearts.
No takes yet. Share an insight, caveat, or question.
Tosaka et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: